

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Encyte Systems, Inc.		06/30/2010	CORPORATION: MASSACHUSETTS
RECEIVING PARTY DATA			
Name:	Biomet Biologics, LLC		
Street Address:	56 East Bell Drive		
City:	Warsaw		
State/Country:	INDIANA		
Postal Code:	46582		
Entity Type:	LIMITED LIABILITY COMPANY: INDIANA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2903195	ENCYTE	
CORRESPONDENCE DATA			
Fax Number:	(248)641-0270		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	248-641-1600		
Email:	docketingtm@hdp.com		
Correspondent Name:	Lisabeth H. Coakley		
Address Line 1:	5445 Corporate Drive, Suite 200		
Address Line 4:	Troy, MICHIGAN 48098		
ATTORNEY DOCKET NUMBER:	5490T-501093		
NAME OF SUBMITTER:	Lisabeth H. Coakley		
Signature:	/lh/		
Date:	08/13/2010		

CH \$40.00 2903195

Total Attachments: 3

source=Assignment - Encyte Systems#page1.tif

source=Assignment - Encyte Systems#page2.tif

source=Assignment - Encyte Systems#page3.tif

TRADEMARK ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Encyte Systems, Inc., a Massachusetts corporation, having an address at 55 Messina Drive, Braintree, Massachusetts, 02184-6783 ("Assignor") ASSIGNS and CONVEYS, effective as of June 30, 2010 (the "Effective Date"), to Biomet Biologics, LLC, an Indiana limited liability company, having an address at 56 East Bell Drive, Warsaw, Indiana 46582 ("Assignee"), Assignor's entire right, title and interest in and to the trademarks, and the registrations and applications therefor, set forth on the attached Schedule A, all goodwill associated with each trademark, and all claims and rights to sue for and collect damages by reason of infringement of each trademark to the extent relating to any period on or after the Effective Date.

Assignor agrees to execute and deliver to Assignee or its designee, any and all documents deemed necessary by Assignee or its designee to transfer ownership of or confer the transfer of ownership of all of the rights, title and interests in and to the applications and the trademarks issued therefrom or corresponding thereto, including all intellectual property rights therein in the United States of America and all foreign countries.

This Assignment is executed and delivered pursuant to that certain Asset Purchase Agreement, dated as of the Effective Date (the "Asset Purchase Agreement"), by and among Assignor, Assignee, Cytosol Laboratories, Inc., Citra Anticoagulants, Inc., Ronald H. Lewis and Biomet, Inc. This Assignment does not alter or amend any of the covenants, representations or warranties of Assignor or Assignee contained in the Asset Purchase Agreement, each of which will survive the execution and delivery of this Assignment as and to the extent provided in the Asset Purchase Agreement.

* * * * *

IN WITNESS WHEREOF, the undersigned has caused this Assignment to be duly executed as of the Effective Date.

ENCYTE SYSTEMS, INC.

Ronald H. Lewis

Name: Ronald H. Lewis

Title: President

COMMONWEALTH OF MASSACHUSETTS)

) SS:

COUNTY OF NORFOLK)

On the 30 day of June 2010, before me, a Notary Public in and for said County and State, personally appeared Ronald H. Lewis and acknowledged that he is the President of enCyte Systems, Inc., that he is authorized by said Corporation to execute the foregoing Assignment on behalf of said Corporation, and that he did execute the foregoing Assignment on behalf of said Corporation, pursuant to such authority.


Notary Public

Printed Name

Isaac M. Davis
ISAAC M DAVIS

County of Residence: NORFOLK

My Commission Expires: 7/7/2011



Schedule A

U.S. Registered Trademarks

enCyte Systems, Inc.

<u>Mark</u>	<u>Reg. No.</u>	<u>Reg. Date</u>	<u>Goods</u>	<u>Status</u>
ENCYTE	2,903,195	November 16, 2004	Pharmaceutical preparations, namely, biochemically reagents used to enhance the functionality of human blood cells, in Class 5	Declaration of Use due between <u>November 16,</u> <u>2009</u> and <u>November 16,</u> <u>2010</u>